Combination Immunotherapy With Radiotherapy in Non‐Small Cell Lung Cancer: A Review of Evidence
Cancer Medicine · 2024-11 · 13 (21)
DOI: 10.1002/cam4.70402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 11.11.2024. Verfasst von Justin L Burr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Radiotherapy plays a fundamental role in the treatment of patients with all stages of non‐small‐cell lung cancer (NSCLC). The emergence of immune checkpoint inhibitors (ICIs) has transformed the standard of care in these patients. The use of ICIs is increasingly utilized in the definitive setting as an adjunct to chemoradiotherapy or surgery and remains a vital component in the treatment of metastatic disease. Despite improvements in patient survival, the use of immunotherapy as monotherapy has shown limited overall response rates with susceptibility to resistance. Radiotherapy has been identified as a viable option to enhance the response rate to ICI and improve outcomes in NSCLC.
Methods
We queried the English PubMed database utilizing variably combined search items including “radiation,” “chemoradiation,” “immune checkpoint,” “immunotherapy,” “stereotactic body radiotherapy,” and “non‐small‐cell lung”. We additionally searched various acceptable alternative terms for similar keywords such as “radiotherapy” in place of “radiation.” These results were subsequently curated for relevance and impact on current treatment paradigms.
Results
In this review, we discuss preclinical and clinical studies relating to combinatorial use of immunotherapy and radiation in NSCLC. These studies are presented in the context of early‐stage, operable stage III, unresectable stage III, and metastatic disease. The majority of the data illustrate promising results regarding the additive or synergistic effects of radiation and immunotherapy with a suggestion that the timing of these treatment modalities is crucial to optimizing outcomes.
Conclusion
While there is now evidence regarding the favorable interplay between radiation and immunotherapy in NSCLC, there remain multiple unanswered questions which are expected to be addressed in ongoing clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID-Profile: Justin L Burr, Kurtis C Johnson, Joseph J Carmicheal, Chi Lin, Apar Kishor Ganti
Zitieren
APA
Burr, J. L., Johnson, K. C., Carmicheal, J. J., Lin, C., & Ganti, A. K. (2024). Combination Immunotherapy With Radiotherapy in Non‐Small Cell Lung Cancer: A Review of Evidence. Cancer Medicine, 13(21). https://doi.org/10.1002/cam4.70402
Vancouver
Burr JL, Johnson KC, Carmicheal JJ, Lin C, Ganti AK. Combination Immunotherapy With Radiotherapy in Non‐Small Cell Lung Cancer: A Review of Evidence. Cancer Medicine. 2024;13(21). doi:10.1002/cam4.70402
BibTeX
@article{Burr2024,
author = {Burr, Justin L and Johnson, Kurtis C and Carmicheal, Joseph J and Lin, Chi and Ganti, Apar Kishor},
title = {Combination Immunotherapy With Radiotherapy in Non‐Small Cell Lung Cancer: A Review of Evidence},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {21},
doi = {10.1002/cam4.70402}
}
EUVIMED